TORL BioTherapeutics welcomes Dr. Howard A. “Skip” Burris III to its Board
TORL BioTherapeutics, LLC (TORL), a biotechnology company focused on antibody-based immunotherapies, has expanded its leadership team. The company has appointed Dr. Howard A. “Skip” Burris III, a widely respected medical oncologist, to its Board of Directors. With decades of experience in oncology and drug development, Dr. Burris joins TORL at a time when the company is sharpening its focus on therapies designed to improve the lives of people with cancer.
Why Dr. Burris’s background fits TORL’s next chapter
Dr. Burris serves as president and chief medical officer of the Sarah Cannon Research Institute (SCRI), an organization known for running innovative, community-based clinical trials in oncology. He’s played a central role in bringing first-in-human therapies into early practice, helping translate scientific promise into clinical progress. TORL’s Board—led by Chairman and CEO Mark J. Alles—welcomed his appointment and underscored how his experience in clinical development and trial leadership aligns with the company’s goals.
A pivotal moment for TORL
Looking ahead to his work with TORL, Dr. Burris described this as a transformative time for the company. TORL is advancing its Antibody-Drug Conjugate (ADC) programs into early and mid-stage clinical trials, and he’s eager to collaborate with fellow board members and management. The shared aim: to accelerate the development of novel cancer treatments that can move efficiently through clinical testing and, ultimately, make a difference for patients.
TORL’s focus and direction
TORL’s leadership believes Dr. Burris’s insights—shaped by years of hands-on drug development—will be especially valuable as clinical programs progress. Board Member and Scientific Co-founder Dennis Slamon, MD, PhD, a leading figure in hematology/oncology at UCLA, emphasized the strategic advantage his perspective brings. Experienced voices like his help TORL keep attention on areas of serious unmet need while making disciplined choices about how to advance its pipeline.
Clinical studies moving forward
TORL BioTherapeutics is conducting multiple clinical studies to evaluate the safety and efficacy of its investigational therapies, including TORL123-001 (Claudin 6 ADC). These studies reflect TORL’s commitment to building a portfolio of high-potential antibody-based treatments. This ongoing research is the backbone of the company’s approach: focused targets, rigorous trial design, and careful progression through each phase of development.
About TORL BioTherapeutics
Founded with a clear goal—deliver meaningful new options to patients—TORL designs antibody-based treatments for a range of malignancies. The company’s work is supported by exclusive partnerships and collaborations, including with the Slamon Research Lab at UCLA. Through this combination of scientific focus and structured development, TORL aims to bring forward therapies that could reshape parts of the cancer care landscape.
Staying centered on patients
With Dr. Burris joining the Board, TORL strengthens its ability to steer complex programs with clinical rigor. The mission remains steady: improve patient outcomes. Each program, each study, and each decision is guided by that aim—bringing measured progress, one step at a time.
Frequently Asked Questions
Who has joined the Board of TORL BioTherapeutics?
Dr. Howard A. “Skip” Burris III has been appointed to TORL’s Board of Directors.
What experience does Dr. Burris bring?
He brings deep experience in oncology and drug development, has led numerous clinical trials, and has authored more than 400 publications.
What kinds of therapies is TORL developing?
TORL develops antibody-based immunotherapies, including monoclonal antibodies and antibody-drug conjugates (ADCs).
How will Dr. Burris contribute to TORL’s work?
His expertise in clinical trial design and drug development will help guide TORL’s programs through early and mid-stage studies and support efforts to demonstrate efficacy and patient benefit.
What’s TORL’s primary goal?
TORL aims to advance innovative cancer therapies that meaningfully improve patient outcomes.
